The Wellcome Trust is an independent global charitable foundation established in 1936 under the will of Sir Henry Wellcome. It funds research to improve human and animal health, with strategic focus areas including discovery research, infectious disease, mental health, and climate and health. Its work is funded by an investment portfolio valued at approximately £39.9 billion.
Their most common stage is series-b (60% of deals). Average disclosed round size is $90.8M (across 5 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
EE
Elaina Elzinga
Principal in Investments
RH
Robert Holl
Principal, Wellcome Investments
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| KKaruna Therapeutics | Series B | $80M | Apr 2019 |
| KKaruna Therapeutics | Series A | $42M | Jan 2018 |
 Nabriva Therapeutics | Ipo | $92M | Sep 2015 |
| Nabriva Therapeutics | Series B | $120M | Apr 2015 |
| NNabriva | Series B | $120M | Jan 2015 |
Top Co-Investors
OrbiMed3 shared
Novartis Venture Fund3 shared
Vivo Capital3 shared
Eventide Asset Management2 shared
Alexandria Venture Investments2 shared
Sofinnova Partners2 shared
Sands Capital2 shared
ARCH Venture Partners2 shared
Boxer Capital2 shared
Pivotal Life Sciences1 shared
PFM Health Sciences1 shared
Hercules Capital, Inc.1 shared
Kreos Capital1 shared
HBM Healthcare Investments1 shared
HBM Partners1 shared
Omega Funds1 shared
Last updated: 20 October 2026